Conference Coverage

ASH: Novel GBT440 reduces sickle cells, improves hematologic parameters

Publish date: December 6, 2015

 

AT ASH 2015

References

Dr. Thompson moderated the briefing in which Dr. Hemmaway presented the data.

The study is supported by Global Blood Therapeutics. Dr. Hemmaway had no relevant disclosures. Several co-investigators are employees of the company. Dr, Thompson had no disclosures relevant to the study.

Pages

Recommended Reading

FDA Approves Deferiprone for Transfusional Iron Overload
MDedge Internal Medicine
Sickle cell crises curtailed with experimental cellular adhesion inhibitor
MDedge Internal Medicine
NHLBI expert panel issues guideline on sickle cell disease
MDedge Internal Medicine
Stem cells from sickle cell disease patients used to generate gene-corrected cells
MDedge Internal Medicine
More than 75% with sickle cell crises don’t get hydroxyurea
MDedge Internal Medicine
Antibiotics to reduce microbiota may improve treatment of sickle-cell disease
MDedge Internal Medicine
ASH: Gene therapy reduces transfusion needs in beta-thalassemia major
MDedge Internal Medicine
ASH: Oral drug offers alternative to lifelong transfusions in sickle cell
MDedge Internal Medicine
ASH: HLA-identical sibling transplants “excellent” in eligble SCD patients
MDedge Internal Medicine